Walgreens Boots Alliance Inc. (US9314271019) stock has transitioned into a legacy holding for investors, as the shares are no longer part of regular Nasdaq trading following a previously announced delisting that identified August 27, 2025 as the last normal trading date. As of August 17, 2026, investors evaluating Walgreens Boots Alliance stock are therefore dealing with a position that no longer benefits from continuous exchange-based price discovery and liquidity.
Delisting turns Walgreens Boots Alliance into a legacy holding
Per a detailed corporate update on August 17, 2026, prior exchange communications signaled that Walgreens Boots Alliance shares would cease regular Nasdaq trading, with August 27, 2025 named as the last trading session for the stock in its standard listing. The corporate news overview explains that this history now shapes how investors must think about Walgreens Boots Alliance stock: rather than a continuously traded large-cap, the position functions as a legacy holding whose value is tied to past operating performance and corporate actions.
The same overview emphasizes that, by August 17, 2026, Walgreens Boots Alliance stock is no longer included in the normal daily Nasdaq price rotation, meaning that intraday highs, lows, and volume statistics familiar from active Nasdaq stocks are no longer produced in the same way. For investors, this shift is material because it affects both the ease of trading and the transparency of real-time price formation, and it raises practical questions about how the position is now handled in brokerage accounts and custodial systems.
Market portals that continue to list Walgreens Boots Alliance under the ticker WBA now do so with cautionary language that the stock may be potentially delisted and not actively trading. A recent market-data overview notes that Walgreens Boots Alliance is marked as potentially delisted, reinforcing the picture painted by exchange notices and corporate news reports that regular trading has ceased.
Legacy pricing references and data context
Despite the lack of regular Nasdaq trading, some market-data platforms still show a reference price for Walgreens Boots Alliance. One trading and data portal lists Walgreens Boots Alliance stock with a price indication of $11.98 and a market capitalization of $10.37 billion as of August 17, 2026. However, the same page highlights that, on August 17, 2026, Walgreens shares started trading with blank entries for intraday high and low, mirroring the delisted or non-actively traded status signaled by other sources.
For investors who still hold WBA, these reference figures play a role similar to valuation anchors rather than live trading benchmarks. A price indication of $11.98 as of August 17, 2026 suggests where the position is valued on that platform, while the market capitalization of $10.37 billion gives context for the company’s scale relative to other healthcare and retail names. At the same time, the absence of active intraday ranges on August 17, 2026 is consistent with the notion that Walgreens Boots Alliance stock is not participating in standard exchange trading.
Another market-data commentary page devoted to Walgreens Boots Alliance reinforces that the company has been marked as potentially delisted and may not be actively trading, which aligns with the exchange and corporate action narrative described in the delisting-focused corporate news piece. The related news overview states that the company has been flagged as potentially delisted, underscoring that any observed price changes are not part of a normal high-liquidity Nasdaq environment.
For comparison, investors can look to active ETFs where Walgreens Boots Alliance might still appear as a component. An ETF analytics page lists WBA among the holdings of a Nasdaq-focused fund and cites a latest ETF price of $103.86 with a one-year return of 3.93% and a three-year return of 7.12%. While these ETF performance statistics do not directly provide a live quote for WBA itself, they illustrate how exposure to Walgreens Boots Alliance can persist indirectly through fund holdings even when the stock’s primary listing has been delisted.
Fundamentals and reporting context framed as history
Because the key catalyst now is the historical delisting and the transition of Walgreens Boots Alliance stock into a legacy holding, present discussions of fundamentals and operating performance are largely framed as historical context. The corporate news summary that highlights the Nasdaq delisting stresses that, by August 17, 2026, investors are looking more at past financial performance and strategic repositioning than at current earnings-based trading reactions. In other words, older revenue and profit figures, which would have been reported for fiscal years or quarters preceding the August 27, 2025 last trading date, now serve as background rather than as live drivers of price discovery.
Within this framework, historical financial statements for Walgreens Boots Alliance – such as fiscal-year results preceding the delisting – provide insight into how the company’s core pharmacy and retail operations performed before the transition away from regular Nasdaq trading. These past numbers can inform an investor’s understanding of why the company may have faced delisting pressures, whether related to share price levels, listing requirements, or strategic decisions. However, any fiscal years that ended more than 24 months before August 17, 2026 must be treated strictly as historical and not as current metrics, which is why they are referenced in a general way here rather than as specific current figures.
For investors comparing Walgreens Boots Alliance to other actively traded healthcare or retail names, the key distinction is that those peers still report quarterly earnings and see their stocks respond in real time, whereas WBA’s past earnings now influence valuation mainly through legacy positions and any remaining over-the-counter or alternative trading mechanisms that may exist. This contrast underscores how important the regular listing status is for turning fresh fundamental data into continuous market signals, and it explains why the delisting date of August 27, 2025 is central to understanding the current situation as of August 17, 2026.
Investor implications of the August 27, 2025 last trading date
The identification of August 27, 2025 as the last regular Nasdaq trading date for Walgreens Boots Alliance stock has several direct implications for investors that remain relevant in August 2026. First, any trading strategies that relied on intraday liquidity, such as short-term momentum trades or intraday hedging, would have had to change once the stock ceased regular exchange trading. Second, margin and collateral treatment of WBA shares may differ following delisting, potentially affecting how brokers and clearing firms assess the position for lending and risk management purposes.
Third, the delisting can influence how index providers treat Walgreens Boots Alliance in major benchmarks. As the corporate news summary notes, by August 17, 2026, Walgreens Boots Alliance is no longer part of the normal daily Nasdaq price rotation, which implies that index committees may have adjusted index membership to reflect the changed trading status. For investors holding index funds or ETFs that previously included WBA, this adjustment matters because it shapes both sector exposure and performance attribution relative to healthcare, consumer staples, and retail baskets.
A fourth implication concerns corporate actions that may have accompanied or followed the delisting. A corporate actions tracker notes that Walgreens Boots Alliance performed a cash and stock merger, indicating that at least part of the delisting story may involve a transaction structure where shareholders received a combination of cash and shares in another entity. Such a merger would affect both ownership and tax treatment for investors, and it could be a reason why the regular Nasdaq listing was terminated.
From an investor perspective, the combination of delisting, corporate actions, and legacy status means that the shares should be viewed in the context of how they now sit within brokerage accounts, custodial systems, and potential successor entities, rather than as an actively traded standalone stock. Where a merger has created a new primary listing elsewhere, the economic value tied to Walgreens Boots Alliance’s former operations may now be captured in that new vehicle, and investors will need to consult their brokers and transaction documentation to understand the exact mapping.
Walgreens Boots Alliance stores and pharmacy operations
Although the stock’s regular Nasdaq listing has been delisted, Walgreens Boots Alliance Inc. remains widely known for its pharmacy and retail operations, particularly in the United States and parts of Europe. The company’s flagship Walgreens stores operate as neighborhood health and wellness destinations that blend prescription dispensing, over-the-counter medications, beauty and personal care products, and general convenience items. For many communities, these stores serve as accessible points for vaccinations, chronic disease management programs, and basic health screenings.
As a representative product and service, Walgreens pharmacies provide prescription medication fulfillment backed by counseling from licensed pharmacists, with integrated digital tools that allow customers to manage refills, check potential drug interactions, and coordinate care with clinicians. These services support recurring revenue streams and customer loyalty, even when the stock itself is no longer actively traded on Nasdaq. The continued operation of these pharmacies and retail stores underscores that delisting a stock does not automatically equate to ceasing business operations; instead, it reflects changes in how ownership interests are represented and traded.
Legacy stock holds a reference price of $11.98
As of August 17, 2026, a key market-data portal lists Walgreens Boots Alliance stock with a reference price of $11.98 and a market capitalization of $10.37 billion, even as the company is flagged as potentially delisted and not actively trading. These figures give investors a sense of how the legacy position is valued on that platform, but they must be interpreted in light of the August 27, 2025 last trading date and the subsequent corporate actions that reshaped the stock’s listing status.
For investors still holding Walgreens Boots Alliance shares, the combination of an indicated price of $11.98 as of August 17, 2026, the legacy market capitalization, and the knowledge that regular Nasdaq trading ceased on August 27, 2025 provides a structured framework for discussions with brokers and financial advisors. The focus is less on intraday price reactions to current earnings releases and more on understanding how the position maps to any successor securities, what rights remain attached to the shares, and how the legacy holding fits into a broader portfolio that may now rely more on actively traded healthcare and consumer names for liquidity and price discovery.
Disclaimer…